Research

Hormonal

Combining Duodenal Mucosal Ablation (DMR) or Electroporation (ReCET) with GLP-1 receptor agonists (like Liraglutide or Semaglutide) can enable a majority of insulin-requiring T2D patients to eliminate exogenous insulin.

If you have Type 2 Diabetes and require insulin, ask your doctor about combining endoscopic procedures (like DMR or ReCET) with GLP-1 medications (like Semaglutide or Liraglutide). This combination has shown high success rates (up to 86% in small studies) in helping patients stop taking insulin. While it involves both a procedure and medication, the goal is to achieve insulin independence and better long-term control. This approach is still emerging, so discuss the risks and benefits with a specialist.

ModerateSupportsMEDIUM confidence
Previously, the same group showed that the combination of DMR and the GLP-1 agonist Liraglutide led to the elimination of exogenous insulin in >50% of patients that was maintained at 18 months... combination of ReCETTM and empirical semaglutide enabled 86% (n = 14) of patients with insulin-requiring T2D to remain off insulin at one year
Benjamin Norton et al. · Gastrointestinal Disorders · 2024

Why this rating

Based on small cohort studies and abstracts; RCTs are ongoing.

Source

Metabolic Endoscopy: Should Gastroenterologists Be Treating Type 2 Diabetes?

Benjamin Norton et al. · Gastrointestinal Disorders · 2024

DOI 10.3390/gidisord6010013

narrative_reviewCited 7×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →